UBS AM
RXRX icon

UBS AM’s Recursion Pharmaceuticals RXRX Stock Holding History

UBS AM’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Sell
760,129
-3,263,269
-81% -$10.9M ﹤0.01% 1910
2026
Q1 		$12.4M Sell
4,023,398
-51,821
-1% -$200K ﹤0.01% 1096
2025
Q4 		$16.7M Sell
4,075,219
-121,759
-3% -$603K ﹤0.01% 912
2025
Q3 		$20.5M Sell
4,196,978
-418,538
-9% -$2.2M ﹤0.01% 816
2025
Q2 		$23.4M Sell
4,615,516
-1,793,008
-28% -$8.81M ﹤0.01% 993
2025
Q1 		$33.9M Buy
6,408,524
+4,149,346
+184% +$30.2M 0.01% 772
2024
Q4 		$15.3M Buy
2,259,178
+118,428
+6% +$796K ﹤0.01% 1062
2024
Q3 		$14.1M Buy
2,140,750
+43,078
+2% +$309K ﹤0.01% 1084
2024
Q2 		$15.7M Buy
2,097,672
+1,891,903
+919% +$16.5M ﹤0.01% 960
2024
Q1 		$2.05M Sell
205,769
-21,104
-9% -$235K ﹤0.01% 1684
2023
Q4 		$2.24M Buy
226,873
+15,297
+7% +$109K ﹤0.01% 1640
2023
Q3 		$1.62M Buy
211,576
+96,298
+84% +$961K ﹤0.01% 1727
2023
Q2 		$769K Hold
115,278
– – ﹤0.01% 2122
2023
Q1 		$769K Buy
115,278
+8,347
+8% +$66.2K ﹤0.01% 2122
2022
Q4 		$824K Buy
106,931
+30,052
+39% +$295K ﹤0.01% 1949
2022
Q3 		$818K Buy
76,879
+25,426
+49% +$258K ﹤0.01% 2086
2022
Q2 		$419K Buy
51,453
+3,259
+7% +$21.8K ﹤0.01% 2364
2022
Q1 		$345K Buy
48,194
+12,741
+36% +$135K ﹤0.01% 2563
2021
Q4 		$607K Buy
+35,453
New +$667K ﹤0.01% 2474

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS AM's RXRX Position: Q2 2026 in Review

UBS AM reduced its Recursion Pharmaceuticals (RXRX) stake by 81% in Q2 2026, selling an estimated $10.9M and leaving 760,129 shares worth $2.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1910.

UBS AM first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $33.9M in Q1 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • UBS AM held 760,129 shares of Recursion Pharmaceuticals worth $2.79M as of Q2 2026.
  • UBS AM sold 3,263,269 Recursion Pharmaceuticals shares in Q2 2026, an estimated $10.9M.
  • Recursion Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1910 holding.
  • UBS AM first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • UBS AM's Recursion Pharmaceuticals position peaked at $33.9M in Q1 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.